cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Lexicon Pharmaceuticals Inc
36 own
29 watching
Current Price
$0
$-0.06
(-1.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
555.42M
52-Week High
52-Week High
3.789
52-Week Low
52-Week Low
1.31
Average Volume
Average Volume
1.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
8.9838
iconMarket Capitalization555.42M
icon52-Week High3.789
icon52-Week Low1.31
iconAverage Volume1.07M
iconDividend Yield--
iconP/E Ratio8.9838
What does the Lexicon Pharmaceuticals Inc do?
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Read More
How much money does Lexicon Pharmaceuticals Inc make?
News & Events about Lexicon Pharmaceuticals Inc.
Globe Newswire
1month ago
Data accepted as AAN Late-Breaking AbstractTHE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of ...
Ticker Report
2 months ago
StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX Get Rating) to a sell rating in a research report released on Saturday. Separately, Jefferies Financial Group started coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 7th. They set a hold ...
Globe Newswire
3 months ago
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection fraction (LVEF) range THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new ...
Globe Newswire
3 months ago
Into the Dark Into the Dark Campaign Image Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American ...
Globe Newswire
3 months ago
Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failureTHE WOODLANDS, Texas, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF...
Frequently Asked Questions
Frequently Asked Questions
What is Lexicon Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Lexicon Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Lexicon Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Lexicon Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Lexicon Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Lexicon Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Lexicon Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Lexicon Pharmaceuticals Inc?
plus_minus_icon
What percentage is Lexicon Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Lexicon Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.06
(-1.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Mesoblast
Mesoblast
$3.54
$-0.05 (-1.39 %)
Coherus BioSciences Inc
Coherus BioSciences Inc
$5.33
$-0.05 (-0.95 %)
NanoString Technologies Inc
NanoString Technologies Inc
$5.71
$-0.45 (-7.24 %)
bluebird bio, Inc.
bluebird bio, Inc.
$3.70
$-0.02 (-0.54 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mesoblast
Mesoblast
$3.54
$-0.05 (-1.39 %)
Coherus BioSciences Inc
Coherus BioSciences Inc
$5.33
$-0.05 (-0.95 %)
NanoString Technologies Inc
NanoString Technologies Inc
$5.71
$-0.45 (-7.24 %)
bluebird bio, Inc.
bluebird bio, Inc.
$3.70
$-0.02 (-0.54 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00